Clinical Study of the Safety and Efficacy of BCMA CAR-NK

NCT05652530 | Unknown Early Phase 1

• 1 other identifier: PRG2101
• Study Type: interventional
• Target: 19
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this clinical trial is to study of the Safety and Efficacy of Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK) in Patients with Relapsed/Refractory Multiple Myeloma Primary Endpoints: To evaluate the safety and tolerability of patients with relapsed/refractory multiple myeloma (RR/MM) after BCMA CAR-NK infusion. To determine the maximum tolerated dose (MTD) and/or subsequent recommended dose (RD) of BCMA CAR-NK in patients with RR/MM. Secondary Endpoints: To preliminarily evaluate the effectiveness of BCMA CAR-NK in patients with RR/MM. To preliminarily evaluate the pharmacokinetic parameters of BCMA CAR-NK cells in patients with RR/MM. To preliminarily evaluate BCMA CAR-NK cell survival in subjects blood in relation to efficacy, adverse events and relevant biomarker levels. To preliminarily evaluate the relationship between donors and subjects KIR-Ligand mismatch and safety \& efficacy. To preliminarily evaluate the impact of the degree of HLA genotype matching between donors and subjects on the survival of BCMA CAR-NK cells in the subjects blood. Subjects are enrolled and treated with lymphocyte clearance chemotherapy (including pre-clearance evaluation), pre-infusion evaluation and BCMA CAR-NK cells infusion and enter the follow-up period after the end of the DLT observation period.

Conditions

Immunotherapy; Multiple Myeloma

Outcome Measures

Primary Outcomes (1)

• Safety and Toxicity Assessment per Adverse Event reporting classified according to CTCAE V5.0

  per Adverse Event reporting classified according to CTCAE V5.0

  Day 28

Study Arms (1)

BCMA CAR-NK

EXPERIMENTAL

Drug: Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK)

Interventions

Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK) DRUG

This product is allogeneic NK cells which are cryopreserved after in vitro CAR genetic modification and scale-up manufacturing. Subjects are enrolled and treated with lymphocyte clearance chemotherapy (including pre-clearance evaluation), pre-infusion evaluation and BCMA CAR-NK cells infusion.

Also known as: Lymphocyte clearance

BCMA CAR-NK

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age 18 years or above, no gender preference.
• Patients who have received at least 3 prior lines of treatment for multiple myeloma and have failed at least proteasome inhibitor and immunomodulator therapy; Each line has at least 1 complete treatment cycle unless the best remission status for that treatment is documented as progressive disease (PD) (as per the IMWG efficacy evaluation criteria published in 2016, Appendix 4); PD must be documented during or within 12 months after receiving the last treatment.
• Presence of measurable lesions at screening, which are defined as any of the following situations:
• Serum M protein≥1 g/dL (≥10 g/L) Urinary M protein≥200 mg/24 hours Serum free light chain (FLC): abnormal serum FLC ratio (\<0.26 or \>1.65) and involved FLC≥10 mg/dL (100 mg/L)
• ECOG score (Appendix 1): 0\~1.
• Expected survival≥3 months.
• The following test values within 7 days prior to lymphocyte clearance meet the following criteria:
• Hematology Absolute lymphocyte count:≥0.5×109/L\[Granulocyte colony-stimulating factor (G-CSF) is allowed, but subjects should not have received this supportive therapy within 7 days prior to laboratory test during the screening period\] Absolute neutrophil count:≥1.0×10\^9 /L\[Granulocyte colony-stimulating factor (G-CSF) is allowed, but subjects should not have received this supportive therapy within 7 days prior to laboratory test during the screening period\].
• Platelets:Subjects platelet count ≥50 x 10\^9/L (subjects must not receive transfusion support within 7 days prior to laboratory test during the screening period) Hemoglobin:≥8.0 g/dL (recombinant human erythropoietin is allowed) \[subjects have not received a red blood cell (RBC) transfusion within 7 days prior to laboratory test during the screening period\].
• Liver Total bilirubin (serum) :Total bilirubin (serum) ≤1.5 × ULN AST and ALT:≤3× ULN
• Peripheral venous pathway meets the requirements of intravenous drip.
• Subjects agree to use reliable methods for contraception from the time of signing the informed consent till 1 year after the transfusion.
• Voluntary participation in the clinical trial and signing of the informed consent form.

You may not qualify if:

• Subjects who have had a severe anaphylactic reaction.
• Subjects who received the following anti-MM therapy within a specific time prior to lymphocyte clearance.
• Small molecule targeted therapy within 2 weeks or 5 half-lives (whichever is longer).
• Large-molecule drug within 4 weeks or 2 half-lives (whichever is longer). Cytotoxic drugs, modern Chinese medicine preparations with antitumor effects within 2 weeks.
• Immunomodulators therapy within 1 week.
• Subjects who have received a live or attenuated vaccine within 4 weeks prior to lymphocyte clearance.
• Subjects who have received the following therapy within 7 days prior to lymphocyte clearance, or that requires long-term treatment during the study period according to the investigators:
• Systemic steroid therapy (except for inhaled one or topical use). Immunosuppressive therapy. Treatment of graft-versus-host response.
• Subjects presenting with incomplete recovery or stabilization to grade 1 (NCI-CTCAE v5.0) of toxicity (including peripheral neuropathy) caused by prior treatments.
• Cardiac disease: episode of myocardial infarction≤6 months prior to lymphocyte clearance; episode of unstable angina, severe arrhythmia as judged by the investigators, or coronary artery bypass graft≤3 months prior to lymphocyte clearance.
• Women who are pregnant or breastfeeding.
• Subjects who, in the opinion of the investigators, have any clinical or laboratory test abnormalities or other reasons that make them ineligible to participate in this clinical study.

Sponsors & Collaborators

• Shenzhen Pregene Biopharma Co., Ltd.: lead

Study Sites (1)

Henan Cancer Hospital

Zhengzhou, Henan, 450000, China

RECRUITING

MeSH Terms

Conditions

Multiple Myeloma

Condition Hierarchy (Ancestors)

Neoplasms, Plasma Cell; Neoplasms by Histologic Type; Neoplasms; Hemostatic Disorders; Vascular Diseases; Cardiovascular Diseases; Paraproteinemias; Blood Protein Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Hemorrhagic Disorders; Lymphoproliferative Disorders; Immunoproliferative Disorders; Immune System Diseases

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 28, 2022
• First Posted: December 15, 2022
• Study Start: November 13, 2022
• Primary Completion: September 30, 2023
• Study Completion: November 30, 2023
• Last Updated: December 15, 2022

Record last verified: 2022-12

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)